<DOC>
	<DOCNO>NCT00809614</DOCNO>
	<brief_summary>This study design proof concept AIN457 patient psoriatic arthritis . The study address evaluation efficacy 6 24 week two dos AIN457 10 mg/kg administer three week apart .</brief_summary>
	<brief_title>Efficacy AIN457 Adults ( 18-65 Years ) With Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>A diagnosis psoriatic arthritis Patients arthritis ankylose spondyitis Druginduced psoriasis Male female patient plan conceive time course study , 6 month administration second dose . Participation clinical trial within 4 week prior initial dosing longer . Previous use immunosuppressive agent eg cyclosporine , without necessary washout period History severe allergy food drug Positive TB test . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Psoriatic arthritis</keyword>
	<keyword>IgG1K monoclonal antibody</keyword>
	<keyword>Interleukin -17A neutralize</keyword>
</DOC>